DISP-10 for Gastrointestinal Cancer

This trial explores a new treatment called DISP-10 for individuals with advanced gastrointestinal cancers, such as esophageal and gastric adenocarcinomas. The goal is to determine the safety and effectiveness of DISP-10, which combines a virus (DV-10) with a special type of immune cell therapy (CAR T cells). The trial consists of two parts to identify the optimal dose and assess its efficacy. Suitable participants include those with specific advanced GI cancers and at least one tumor that can be biopsied. As a Phase 1 trial, this research aims to understand how the treatment functions in people, offering participants the chance to be among the first to receive this innovative therapy.

The trial information does not specify if you need to stop taking your current medications. However, it does mention that active treatment with antiviral agents is not allowed, so you may need to stop those if applicable.

Research has shown that the DISP-10 treatment, which combines a virus targeting cancer cells and a cell therapy targeting a protein on these cells, is under study for safety in people with advanced gastrointestinal cancers. As a Phase 1 trial, the primary goal is to assess the treatment's safety and tolerability in humans.

In early studies with similar treatments, researchers often identify side effects and determine safe dose levels. While side effects may occur, they are closely monitored. These studies aim to find the right dose that balances effectiveness with safety. Although specific data on DISP-10 side effects is not yet available, similar therapies can sometimes cause reactions like fever or tiredness.

Unlike the standard treatments for gastrointestinal cancer, which often include surgery, chemotherapy, and radiation, DISP-10 offers a novel approach by combining a new active ingredient, DV-10, with ide-cel, a type of CAR-T cell therapy. Most traditional treatments target cancer cells directly, but DISP-10 works by enhancing the immune system's ability to fight cancer through genetically modified T-cells. Researchers are excited about DISP-10 because it could provide a more personalized and potentially more effective treatment option with fewer side effects than conventional therapies.

Research has shown that DISP-10, which participants in this trial will receive, combines DV-10 (a type of virus) and idecabtagene vicleucel (a type of immune therapy). This immune therapy, known as CAR T-cell therapy, boosts the body's natural defenses to target and destroy cancer cells. Studies have found that these therapies can significantly shrink tumors in other types of cancer. Viruses like DV-10 deliver treatment directly into cancer cells, aiding in their destruction. Early evidence from similar treatments suggests they may slow cancer growth and improve patient outcomes. This combination aims to attack cancer cells in different ways, increasing the chances of success.¹³⁶⁷⁸